Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway

Cancer Biology and Therapy

Volumn 10, Issue 6, 2010, Pages 632-643

  Wang, Xi ^a   Ren, Ji Hong ^a   Lin, Fang ^a   Wei, Jun Xia ^a   Long, Min ^a   Yan, Lin ^a   Zhang, Hui Zhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Cervical cancer; PI3K Akt; Stathmin

Indexed keywords

ARSENIC TRIOXIDE; COMPLEMENTARY DNA; CYTOCHROME C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; STATHMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SOLID TUMOR; UTERINE CERVIX CANCER; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; HELA CELLS; HUMANS; IN SITU NICK-END LABELING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STATHMIN; SURVIVAL ANALYSIS; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957119311     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.6.12654     Document Type: Article

References (34)

1. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present and future. Leuk Res 2004; 28:891-900.
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-60. (Pubitemid 32880064)
3. Ai Z, Lu W, Qin X. Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2. Biochem. Biophys Res Commun 2006; 348:1075-81.
4. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Arsenic Trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reprod Sci 2008; 15:1011-7.
5. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97:675-81. (Pubitemid 44056616)
6. 3) in endometrial carcinoma cells. Gynecol Oncol 2007; 105:218-22.
7. Wang X, Wang G, Dong D, Fu S, Yang B. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide. Exp Toxicol Pathol 2008; 60:481-8.
8. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Bio chem 2004; 93:242-50.
9. Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Song GA, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010; 102:710-8.
10. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther 2006; 5:3248-57.
11. Hanash SM, Strahler JR, Kuick R, Chu EH, Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 1988; 263:12813-5.
12. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM. Characterization of the gene for a proliferationrelated phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 1991; 266:17747-53.
13. Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 2003; 22:8924-30. (Pubitemid 38021508)
14. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther 2006; 5:3248-57.
15. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000; 83:311-8.
16. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2006; 26:1003-12.
17. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2007; 94:17-23.
18. Wei SH, Lin F, Wang X, Gao P, Zhang HZ. Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem 2008; 110:59-65.
19. Zhang HZ, Gao P, Yan L, Lin F. Significance of stathmin gene overexpression in osteosarcoma cells. Ai Zheng 2004; 23:493-6.
20. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 2009; 135:837-46.
21. Zhang HZ, Wang Y, Gao P, Lin F, Liu L, Yu B, et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 2006; 5:1457-61.
22. Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med 2007; 13:567-75.
23. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, et al. Stathmin activity influences sarcoma cell shape, motility and metastatic potential. Mol Biol Cell 2008; 19:2003-13.
24. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785:96-132.
25. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26:1003-12. (Pubitemid 46272214)
26. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005; 65:8350-8.
27. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9:667-76.
28. Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003; 7:205-728. (Pubitemid 37466220)
29. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10:2846-50.
30. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcoming among endocrine treated patients. Br J Cancer 2002; 86:540-5.
31. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004; 64:3486-90.
32. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005; 105:4013-20. (Pubitemid 40656150)
33. Tabellini G, Tazzari PL, Bortul R, Evangelisti C, Billi AM, Grafone T, et al. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br J Haematol 2005; 130:716-25.
34. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104:7564-9.